Literature DB >> 24602953

Challenges in the management of infections due to carbapenem-resistant Enterobacteriaceae.

Dimitri M Drekonja1, Susan E Beekmann, Sean Elliott, Deepa Mukundan, Hari Polenakovik, Marnie E Rosenthal, Pranita D Tamma, Philip M Polgreen, Scott J Weissman.   

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) infections are increasing and are associated with considerable morbidity and mortality. Members of the Emerging Infections Network treating CRE encountered difficulties in obtaining laboratory results and struggled with limited treatment options. In addition, many treated patients experienced an alarming degree of drug toxicity from CRE therapies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24602953     DOI： 10.1086/675604

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  5 in total

1.  In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Authors:  Yunliang Zhang; Xiaoyan Lin; Karen Bush
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  The growing threat of carbapenem resistant enterobacteriaceae (CRE) within in-patient spinal rehabilitation units.

Authors:  Priyadarshini Chari; Anna Seruga; Nelson Nathan; David M Bowers
Journal:  Spinal Cord Ser Cases       Date:  2016-07-07

3.  Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.

Authors:  Pia S Pannaraj; Jennifer Dien Bard; Chiara Cerini; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

4.  The pros, cons, and unknowns of search and destroy for carbapenem-resistant enterobacteriaceae.

Authors:  Prashini Moodley; Andrew Whitelaw
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

5.  Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.

Authors:  John S Bradley; Jon Armstrong; Antonio Arrieta; Raafat Bishai; Shampa Das; Shirley Delair; Timi Edeki; William C Holmes; Jianguo Li; Kathryn S Moffett; Deepa Mukundan; Norma Perez; José R Romero; David Speicher; Janice E Sullivan; Diansong Zhou
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.